Literature DB >> 8005183

Influence of input rates on (+/-)-isradipine haemodynamics and concentration-effect relationship in healthy volunteers.

V Carrara1, H Porchet, P Dayer.   

Abstract

Since the magnitude of the response to a drug may depend upon the drug input rate, the concentration-effect relationship of the new dihydropyridine (+/-)-isradipine was investigated using different administration modalities. Ten normotensive healthy volunteers were given, double-blind and in a crossover fashion, isradipine as a 1 mg iv infusion, 5 mg oral solution, 5 mg standard tablet, 10 mg slow release formulation, and a placebo. Blood pressure, heart rate, and plasma isradipine concentrations were recorded for 24 h. The maximal fall in diastolic blood pressure was similar after the infusion (-11.40 mmHg), the oral solution (-15.20 mmHg), and the standard tablet (-12.50 mmHg). In healthy volunteers the slow release form had no significant effect on blood pressure. The concentration-effect plots showed an increasing slope in the order infusion, solution, and table, and anticlockwise hysteresis. This was partly due to marked heart rate counter-regulation, the corresponding mean maximal heart rate increases being 24, 19, and 17 beats.min-1. The pronounced counter-regulation of the heart rate implies that a slow isradipine input rate would be more effective in decreasing blood pressure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005183     DOI: 10.1007/BF00195912

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Holford NHG and Sheiner LB "Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models", Clin Pharmacokin 6:429-453 (1981)-The Backstory.

Authors:  Nick Holford
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

2.  Effects of the new calcium entry blocker isradipine (PN 200-110) in essential hypertension.

Authors:  J Staessen; P Lijnen; R Fagard; P Hespel; W P Tan; P Devos; A Amery
Journal:  J Cardiovasc Pharmacol       Date:  1989-02       Impact factor: 3.105

3.  The pharmacokinetics of oral isradipine in normal volunteers.

Authors:  G D Clifton; R A Blouin; C Dilea; H F Schran; A E Hassell; L M Gonasun; T S Foster
Journal:  J Clin Pharmacol       Date:  1988-01       Impact factor: 3.126

4.  Hemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine.

Authors:  W Kiowski; O Bertel; P Erne; P Bolli; U L Hulthén; R Ritz; F R Bühler
Journal:  Hypertension       Date:  1983 Mar-Apr       Impact factor: 10.190

5.  Rapid resetting of the aortic baroreceptors in the rabbit and its implications for short-term and longer term reflex control.

Authors:  P K Dorward; M C Andresen; S L Burke; J R Oliver; P I Korner
Journal:  Circ Res       Date:  1982-03       Impact factor: 17.367

Review 6.  Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

7.  Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans.

Authors:  C H Kleinbloesem; P van Brummelen; M Danhof; H Faber; J Urquhart; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

8.  Study designs for dose-ranging.

Authors:  L B Sheiner; S L Beal; N C Sambol
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

9.  The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man.

Authors:  J van Harten; P van Brummelen; R R Zeegers; M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

10.  1-Hydrazinophthalazine (apresoline) in hypertension.

Authors:  E HARRIS; R TURNER
Journal:  Lancet       Date:  1954-02-27       Impact factor: 79.321

View more
  4 in total

1.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

2.  Are we doing too many animal biodisposition investigations before phase I studies in man? A re-evaluation of the timing and extent of ADME studies.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jul-Sep       Impact factor: 2.441

Review 3.  Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

Review 4.  Post-Translational Modification of Cav1.2 and its Role in Neurodegenerative Diseases.

Authors:  Yun Li; Hong Yang; Tianhan He; Liang Zhang; Chao Liu
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.